Listen on the go
CORRECT!
Next question
touchDERMATOLOGY touchDERMATOLOGY

Start Learning

Touch Loading image
Pyoderma gangrenosum, Benjamin Kaffenberger
JOURNALS
Start Learning
Latest encouraging vilobelimab data in pyoderma gangrenosum
JOURNALS
Start Learning
From Clinic to CNN: Dr. Shari Lipner’s Journey in Advancing Nail Disorders and Mentoring Future Leaders
chronic spontaneous urticaria dupilumab
JOURNALS
Start Learning
Pooled phase III data reinforce dupilumab’s efficacy in H1-antihistamine refractory chronic spontaneous urticaria
touchMEETING HIGHLIGHTS
Start Learning
ADVENT at ESPD 2024: Type 2 Inflammation in Atopic Dermatitis and the Benefits of Early Intervention
Sponsored content
Early-onset atopic dermatitis
JOURNALS
Start Learning
Specific cord-blood DNA methylation patterns associated with risk of early-onset atopic dermatitis
Pyoderma gangrenosum
JOURNALS
Start Learning
Rare disease round-up: Pyoderma gangrenosum
JOURNALS
Start Learning
Breakthroughs in melanoma: Highlights from ASCO 2024
JOURNALS
Start Learning
New study links rosacea with increased risk of malignant melanoma
touchMEETING HIGHLIGHTS
Start Learning
Pathophysiological mechanisms and emerging concepts in the management of Type 2 dermatological diseases
Sponsored content
oral lichen planus
JOURNALS
Start Learning
New data in oral lichen planus shows LP-310 oral tacrolimus reduces pain, ulceration and inflammation

to view Favourites, Keep Notes and Track CME Credits

Favourites
Greatest Hits of 2024
View
Barzolvolimab shows sustained efficacy over 52 weeks in antihistamine-refractory chronic spontaneous urticaria
View
Breakthroughs in melanoma: Highlights from ASCO 2024
View
Navigating the management of cholestatic pruritus in patients with PBC: Insights from the multidisciplinary team
View
Breaking new ground in CSU treatment: Highlights from EAACI 2024
View
Supporting healing in epidermolysis bullosa: Innovations and new directions for care
View
Global impact, Brazilian roots: Prof. Ensina’s journey leading innovation in allergy and immunology
View
Latest encouraging vilobelimab data in pyoderma gangrenosum
View
Navigating treatment choices in high-risk early-stage melanoma
View
Journal spotlight: Recent literature highlights
View
Copied to clipboard!
accredited arrow-down-editablearrow-downarrow_leftarrow-right-bluearrow-right-dark-bluearrow-right-greenarrow-right-greyarrow-right-orangearrow-right-whitearrow-right-bluearrow-up-orangeavatarcalendarchevron-down consultant-pathologist-nurseconsultant-pathologistcrosscrossdownloademailexclaimationfeedbackfiltergraph-arrowinterviewslinkmdt_iconmenumore_dots nurse-consultantpadlock patient-advocate-pathologistpatient-consultantpatientperson pharmacist-nurseplay_buttonplay-colour-tmcplay-colourAsset 1podcastprinter scenerysearch share single-doctor social_facebooksocial_googleplussocial_instagramsocial_linkedin_altsocial_linkedin_altsocial_pinterestlogo-twitter-glyph-32social_youtubeshape-star (1)tick-bluetick-orangetick-red tick-whiteticktimetranscriptup-arrowwebinar Sponsored Department Location NEW TMM Corporate Services Icons-07NEW TMM Corporate Services Icons-08NEW TMM Corporate Services Icons-09NEW TMM Corporate Services Icons-10NEW TMM Corporate Services Icons-11NEW TMM Corporate Services Icons-12Salary £ TMM-Corp-Site-Icons-01TMM-Corp-Site-Icons-02TMM-Corp-Site-Icons-03TMM-Corp-Site-Icons-04TMM-Corp-Site-Icons-05TMM-Corp-Site-Icons-06TMM-Corp-Site-Icons-07TMM-Corp-Site-Icons-08TMM-Corp-Site-Icons-09TMM-Corp-Site-Icons-10TMM-Corp-Site-Icons-11TMM-Corp-Site-Icons-12TMM-Corp-Site-Icons-13TMM-Corp-Site-Icons-14TMM-Corp-Site-Icons-15TMM-Corp-Site-Icons-16TMM-Corp-Site-Icons-17TMM-Corp-Site-Icons-18TMM-Corp-Site-Icons-19TMM-Corp-Site-Icons-20TMM-Corp-Site-Icons-21TMM-Corp-Site-Icons-22TMM-Corp-Site-Icons-23TMM-Corp-Site-Icons-24TMM-Corp-Site-Icons-25TMM-Corp-Site-Icons-26TMM-Corp-Site-Icons-27TMM-Corp-Site-Icons-28TMM-Corp-Site-Icons-29TMM-Corp-Site-Icons-30TMM-Corp-Site-Icons-31TMM-Corp-Site-Icons-32TMM-Corp-Site-Icons-33TMM-Corp-Site-Icons-34TMM-Corp-Site-Icons-35TMM-Corp-Site-Icons-36TMM-Corp-Site-Icons-37TMM-Corp-Site-Icons-38TMM-Corp-Site-Icons-39TMM-Corp-Site-Icons-40TMM-Corp-Site-Icons-41TMM-Corp-Site-Icons-42TMM-Corp-Site-Icons-43TMM-Corp-Site-Icons-44TMM-Corp-Site-Icons-45TMM-Corp-Site-Icons-46TMM-Corp-Site-Icons-47TMM-Corp-Site-Icons-48TMM-Corp-Site-Icons-49TMM-Corp-Site-Icons-50TMM-Corp-Site-Icons-51TMM-Corp-Site-Icons-52TMM-Corp-Site-Icons-53TMM-Corp-Site-Icons-54TMM-Corp-Site-Icons-55TMM-Corp-Site-Icons-56TMM-Corp-Site-Icons-57TMM-Corp-Site-Icons-58TMM-Corp-Site-Icons-59TMM-Corp-Site-Icons-60TMM-Corp-Site-Icons-61TMM-Corp-Site-Icons-62TMM-Corp-Site-Icons-63TMM-Corp-Site-Icons-64TMM-Corp-Site-Icons-65TMM-Corp-Site-Icons-66TMM-Corp-Site-Icons-67TMM-Corp-Site-Icons-68TMM-Corp-Site-Icons-69TMM-Corp-Site-Icons-70TMM-Corp-Site-Icons-71TMM-Corp-Site-Icons-72
Close Popup